Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.

Yang SM, Yoshioka M, Strovel JW, Urban DJ, Hu X, Hall MD, Jadhav A, Maloney DJ.

Bioorg Med Chem Lett. 2019 May 15;29(10):1220-1226. doi: 10.1016/j.bmcl.2019.03.014. Epub 2019 Mar 12.

PMID:
30905542
2.

Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK.

Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12.

PMID:
30420565
3.

Discovery and lead identification of quinazoline-based BRD4 inhibitors.

Yang SM, Urban DJ, Yoshioka M, Strovel JW, Fletcher S, Wang AQ, Xu X, Shah P, Hu X, Hall MD, Jadhav A, Maloney DJ.

Bioorg Med Chem Lett. 2018 Nov 15;28(21):3483-3488. doi: 10.1016/j.bmcl.2018.08.039. Epub 2018 Aug 31.

PMID:
30268702
4.

CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model.

Imayoshi N, Yoshioka M, Chauhan J, Nakata S, Toda Y, Fletcher S, Strovel JW, Takata K, Ashihara E.

Biochem Biophys Res Commun. 2017 Mar 4;484(2):262-268. doi: 10.1016/j.bbrc.2017.01.088. Epub 2017 Jan 20.

5.

BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.

Chen L, Yap JL, Yoshioka M, Lanning ME, Fountain RN, Raje M, Scheenstra JA, Strovel JW, Fletcher S.

ACS Med Chem Lett. 2015 May 18;6(7):764-9. doi: 10.1021/acsmedchemlett.5b00084. eCollection 2015 Jul 9.

6.

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model.

Yao H, Ashihara E, Strovel JW, Nakagawa Y, Kuroda J, Nagao R, Tanaka R, Yokota A, Takeuchi M, Hayashi Y, Shimazaki C, Taniwaki M, Strand K, Padia J, Hirai H, Kimura S, Maekawa T.

Blood Cancer J. 2011 Nov;1(11):e43. doi: 10.1038/bcj.2011.41. Epub 2011 Nov 4.

7.

Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.

Nagao R, Ashihara E, Kimura S, Strovel JW, Yao H, Takeuchi M, Tanaka R, Hayashi Y, Hirai H, Padia J, Strand K, Maekawa T.

Cancer Lett. 2011 Dec 15;312(1):91-100. doi: 10.1016/j.canlet.2011.08.002. Epub 2011 Aug 17.

8.

Characterization of frequently deleted 6q locus in prostate cancer.

Sun M, Srikantan V, Ma L, Li J, Zhang W, Petrovics G, Makarem M, Strovel JW, Horrigan SG, Augustus M, Sesterhenn IA, Moul JW, Chandrasekharappa S, Zou Z, Srivastava S.

DNA Cell Biol. 2006 Nov;25(11):597-607.

PMID:
17132090
9.

Expression biomarkers for clinical efficacy and outcome prediction in cancer.

Strand KJ, Khalak H, Strovel JW, Ebner R, Augustus M.

Pharmacogenomics. 2006 Jan;7(1):105-15. Review.

PMID:
16354128
10.

Distinct functions of two isoforms of a homeobox gene, BP1 and DLX7, in the regulation of the beta-globin gene.

Fu S, Stevenson H, Strovel JW, Haga SB, Stamberg J, Do K, Berg PE.

Gene. 2001 Oct 31;278(1-2):131-9.

PMID:
11707330
11.

Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene.

Chase MB, Haga SB, Hankins WD, Williams DM, Bi Z, Strovel JW, Obriecht C, Berg PE.

Am J Hematol. 1999 Jan;60(1):27-35.

12.

Supplemental Content

Loading ...
Support Center